We are live on ! Find out more
SWTX

SpringWorks Therapeutics

Delisted

SWTX was delisted on the 30th of June, 2025.

143 hedge funds and large institutions have $1.36B invested in SpringWorks Therapeutics in 2022 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 62 increasing their positions, 35 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 35

35% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 23

11.6% more ownership

Funds ownership: 100.27%111.87% (+12%)

4% more funds holding

Funds holding: 137143 (+6)

30% less call options, than puts

Call options by funds: $1.32M | Put options by funds: $1.87M

43% less funds holding in top 10

Funds holding in top 10: 74 (-3)

51% less capital invested

Capital invested by funds: $2.79B → $1.36B (-$1.43B)

Holders
143
Holders Change
+6
Holders Change %
+4.38%
% of All Funds
2.4%
Holding in Top 10
4
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-42.86%
% of All Funds
0.07%
New
31
Increased
62
Reduced
35
Closed
23
Calls
$1.32M
Puts
$1.87M
Net Calls
-$552K
Net Calls Change
-$4.21M

SWTX Hedge Fund Activity: Q2 2022 in Review

143 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q2 2022, worth a combined $1.36B — down 51% from $2.79B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new SWTX positions and 23 closed out — a net gain of 8 holders — while 62 added to existing stakes and 35 trimmed.

The largest buyer was State Street, adding an estimated $83.9M. The largest seller was Adage Capital Partners, cutting an estimated $47.6M.

  • 143 institutional investors held SpringWorks Therapeutics (SWTX) as of Q2 2022, up from 137 in Q1 2022.
  • Funds reported $1.36B of SpringWorks Therapeutics stock for Q2 2022, down 51% quarter-over-quarter.
  • 31 funds opened new SpringWorks Therapeutics positions in Q2 2022 and 23 closed out, a net change of +8 holders.
  • The largest SpringWorks Therapeutics buyer in Q2 2022 was State Street, an estimated $83.9M added.
  • The largest SpringWorks Therapeutics seller in Q2 2022 was Adage Capital Partners, an estimated $47.6M sold.

Based on aggregated 13F filings for Q2 2022.